Jonathan Peacock serves as the Chairman of our Board of Directors. Previously, Mr. Peacock served as both President and Chief Executive Officer as well as Chairman of our Board of Directors. Prior to joining us, Mr. Peacock served as the Chief Financial Officer of Amgen from August 2010 to January 2014. From 2005 to 2010, he served as Chief Financial and Administrative Officer of Novartis Pharmaceuticals AG, the Pharmaceutical and Biotechnology Division of Novartis AG. Mr. Peacock was also a partner at McKinsey and Co, the strategy consulting firm from 1998 to 2005 and a partner at Price Waterhouse from 1993 to 1998.
Mr. Peacock received an M.A. degree in economics from the University of St. Andrews.
Chief Executive Officer
Mr. Tenenbaum serves as our Chief Executive Officer. Previously, Mr. Tenenbaum served as our Chief Financial Officer and Chief Business Officer. Prior to joining Bellerophon, Mr. Tenenbaum served as Chief Financial Officer and Chief Business Officer of Anterios, Inc., a clinical-stage biopharmaceutical company, from 2014 to 2016. Prior to that, Mr. Tenenbaum served as Chief Executive Officer with Syneron Beauty from 2011 to 2014, and Chief Financial Officer and Executive Vice President of Syneron Medical from 2007 to 2011. Prior to Syneron Medical, Mr. Tenenbaum was Vice President Americas for Radiancy, Inc., from 2002 to 2006, and Director, Commercial Operations and Corporate Development at Sunlight Medical, Inc. from 1999 to 2002.
Mr. Tenenbaum holds a Bachelor in Medicine (B.Md.) from Ben Gurion University, Israel and an MBA from Columbia Business School.
Hunter Gillies, M.D.
Acting Chief Medical Officer
Hunter Gillies, M.D. joined us as our Acting Chief Medical Office in October 2018. Prior to joining us, Dr. Gillies spent more than 20 years in the pharmaceutical and biotech industry working on early and late phase clinical drug development. Having spent time training in nephrology, he left the NHS in the U.K and joined Pfizer in 1998 where he worked on the PDE5 inhibitor programs supporting the development of sildenafil and back up compounds in both cardiovascular and pulmonary vascular disease indications. In 2010 he joined Gilead Sciences where he led the pulmonary vascular disease program. In 2016 he became an independent consultant to several small biotech start-ups working predominantly in early development across diverse therapeutic areas. Dr. Gillies is trained in internal medicine, exercise physiology and sport medicine.
Chief Regulatory and Safety Officer
Peter Fernandes has been our Chief Regulatory Officer since May 2015. In this role he will also manage safety for the company and is the Executive Lead for the INOpulse drug-device combination development program. Prior to joining Bellerophon, Peter was Vice President of Global Regulatory Affairs at Ikaria Inc., from October 2012 to May 2015, and in this capacity also led Bellerophon’s regulatory group since its inception in February of 2014. Previously, he led Regulatory Affairs and Quality Assurance for OptiNose, Inc., was Vice President US Drug Regulatory Affairs Respiratory and US DRA Respiratory Franchise Head for Novartis Pharmaceuticals. He has also served as the Head of US Development Site and Vice President of Regulatory Affairs and Quality Assurance at Altana Pharma, a subsidiary of Nycomed Inc., and led the US Respiratory and GI Drug Regulatory Affairs group at Boehringer Ingelheim.
Peter has an M. Pharm. from the Grant Medical College and a B. Pharm. from the K.M. K College of Pharmacy, both at the University of Bombay in India.
Chief Financial Officer
Assaf Korner joined us as our Chief Financial Officer and Principal Financial Officer in January 2018. Prior to joining Bellerophon, Mr. Korner served as the Chief Financial Officer of L&R Distributors, since February 2016. Prior to that, Mr. Korner served as the Chief Financial Officer of Iluminage Beauty, a medical device Joint Venture between Unilever and Syneron Medical, from 2011 through January 2016. Prior to Iluminage, Mr. Korner held several senior finance roles in Syneron Medical from 2005 through 2011. Prior to Syneron Medical, Mr. Korner served as a Senior Auditor at KPMG.
Mr. Korner holds an MBA from Tel-Aviv University, Israel, a Bachelor’s degree in Accounting and Economics from Haifa University, Israel and is a Certified Public Accountant.
Parag Shah, Ph.D.
Vice President, Business Operations
Parag Shah, Ph.D. has served as our Vice President of Business Operations since April 2016 with responsibilities for Project Management, Supply Distribution, Pre-Clinical and Business Development activities. Prior to joining Bellerophon, Dr. Shah was Principal Scientist at Pfizer from 2004 through 2010 where he was responsible for leading multiple parenteral and liquid formulation development teams. In addition, Dr. Shah was a member of multiple Limited Duration Teams including serving as Pfizer’s Team Lead for the Nanoparticle Network responsible for internal and external evaluation of nanoparticle technologies. Dr. Shah joined Ikaria as Parenteral Development Lead in 2010 and assumed additional responsibilities in 2012 as Director, Pharmaceutical Science, covering both Pharmaceutical Development and Clinical Supply Management.
Dr. Shah received his Bachelor’s degree from Carnegie Mellon and his Ph.D. in Chemical Engineering from The University of Texas at Austin.
Vice President, Engineering and Manufacturing
Martin Dekker has served as our Vice President of Engineering and Manufacturing since January 2015. Prior to joining us, Mr. Dekker held several positions at Spacelabs Healthcare, a company that develops and manufacturers medical devices, from November 1998 to January 2015, most recently as Director of Global Operations Engineering. During his time at Spacelabs Healthcare, Mr. Dekker led and co-designed new products, developed and launched transformative manufacturing technologies and championed cross-functional quality/engineering projects. He is a member of the Institute of Electrical and Electronic Engineers.
Mr. Dekker received a B.S. in electronics from Noordelijke Hogeschool Leeuwarden, the Netherlands.
Vice President, Clinical Operations and Administration
Amy Edmonds has served as our Vice President of Clinical Operations and Administration since September 2015 with responsibilities for Clinical Operations, Contracts & Outsourcing, Human Resources and Information Technology. Ms. Edmonds has over twenty years of global Clinical Operations and Training experience. Prior to Bellerophon, Ms. Edmonds was responsible for Ikaria’s Clinical Operations and Contracts & Outsourcing departments and held several positions of increasing responsibility at Celgene from November 2002 through October 2012. During her time at Celgene, Ms. Edmonds served as Global Clinical Operations Lead for the Americas for multiple therapeutic programs, the Head of North America Monitoring, and the Head of Clinical Operations Training. Ms. Edmonds has also worked in Clinical Operations and Training for Pfizer, Knoll Pharmaceuticals and ICON Clinical Research.
Ms. Edmonds holds a Bachelor’s degree from the University of Richmond.